Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $44000.0.

  • Amphastar Pharmaceuticals' Long-Term Debt Repayments rose 731.71% to $44000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $234000.0, marking a year-over-year decrease of 9959.86%. This contributed to the annual value of $8.3 million for FY2024, which is 9740.69% down from last year.
  • Amphastar Pharmaceuticals' Long-Term Debt Repayments amounted to $44000.0 in Q3 2025, which was up 731.71% from $37000.0 recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Long-Term Debt Repayments high stood at $200.1 million for Q3 2023, and its period low was $37000.0 during Q2 2025.
  • Moreover, its 5-year median value for Long-Term Debt Repayments was $593000.0 (2022), whereas its average is $19.2 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Long-Term Debt Repayments soared by 3908125.0% in 2023 and then plummeted by 9997.95% in 2024.
  • Amphastar Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $613000.0 in 2021, then plummeted by 79.12% to $128000.0 in 2022, then skyrocketed by 39081.25% to $50.2 million in 2023, then plummeted by 99.77% to $115000.0 in 2024, then tumbled by 61.74% to $44000.0 in 2025.
  • Its last three reported values are $44000.0 in Q3 2025, $37000.0 for Q2 2025, and $38000.0 during Q1 2025.